日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Bacterial colonization of tumors drives immune activation and checkpoint blockade efficacy

肿瘤的细菌定植会激活免疫反应并增强免疫检查点阻断的疗效。

Rolig, Annah S; Ziglari, Tahereh; McGee, Grace Helen; Kasiewicz, Melissa J; Kolbaba, Kenna; Simons, Noah D; Pucilowska, Joanna; Sfanos, Karen; Redmond, William L

The response to anti-PD-1 and anti-LAG-3 checkpoint blockade is associated with regulatory T cell reprogramming

抗PD-1和抗LAG-3检查点阻断疗法的疗效与调节性T细胞重编程有关。

Rolig, Annah S; Peng, Xiyu; Sturgill, Elizabeth R; Holay, Nisha; Kasiewicz, Melissa; Mick, Courtney; Mcgee, Grace Helen; Miller, William; Koguchi, Yoshinobu; Kaufmann, Johanna; Yanamandra, Niranjan; Griffin, Sue; Smothers, James; Adamow, Matthew; Lee, Jasme; Shen, Ronglai; Callahan, Margaret K; Redmond, William L

SITC vision: Opportunities for deeper understanding of mechanisms of anti-tumor activity, toxicity, and resistance to optimize cancer immunotherapy

SITC愿景:深入了解抗肿瘤活性、毒性和耐药机制,从而优化癌症免疫疗法。

Sullivan, Ryan J; Cillo, Anthony R; Ferris, Robert L; Jenkins, Russell W; Kluger, Harriet M; Kok, Marleen; Lipson, Evan J; Paruzzo, Luca; Redmond, William L; Ruella, Marco; Schalper, Kurt A; Thommen, Daniela S; Tolley, Keith; Yarchoan, Mark; Garnett-Benson, Charlie

INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clustering

INBRX-106:一种六价OX40激动剂,可通过优化受体聚集驱动更强的抗肿瘤反应

Holay, Nisha; Yadav, Rashi; Ahn, Sae Jeong; Kasiewicz, Melissa J; Polovina, Anya; Rolig, Annah S; Staebler, Thi; Becklund, Bryan; Simons, Noah D; Koguchi, Yoshinobu; Eckelman, Brendan P; de Durana, Yaiza Diaz; Redmond, William L

Current landscape and future prospects of interleukin-2 receptor (IL-2R) agonists in cancer immunotherapy

白细胞介素-2受体(IL-2R)激动剂在癌症免疫治疗中的现状及未来前景

Tanigawa, Kengo; Redmond, William L

Challenges and opportunities in the development of combination immunotherapy with OX40 agonists

OX40激动剂联合免疫疗法开发中的挑战与机遇

Redmond, William L

Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor

利用半乳糖凝集素-3抑制剂贝拉普汀增强抗PD-1的临床和免疫学效应

Curti, Brendan D; Koguchi, Yoshinobu; Leidner, Rom S; Rolig, Annah S; Sturgill, Elizabeth R; Sun, Zhaoyu; Wu, Yaping; Rajamanickam, Venkatesh; Bernard, Brady; Hilgart-Martiszus, Ian; Fountain, Christopher B; Morris, George; Iwamoto, Noriko; Shimada, Takashi; Chang, ShuChing; Traber, Peter G; Zomer, Eliezer; Horton, J Rex; Shlevin, Harold; Redmond, William L

Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab.

血清中伊匹木单抗谷浓度可作为晚期黑色素瘤患者接受伊匹木单抗治疗后临床疗效的潜在生物标志物

Koguchi Yoshinobu, Iwamoto Noriko, Shimada Takashi, Chang Shu-Ching, Cha John, Curti Brendan D, Urba Walter J, Piening Brian D, Redmond William L

A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone

一项针对接受恩扎卢胺单药治疗后病情进展的转移性去势抵抗性前列腺癌男性患者的II期单臂研究,评估帕博利珠单抗联合恩扎卢胺的疗效。

Graff, Julie N; Beer, Tomasz M; Alumkal, Joshi J; Slottke, Rachel E; Redmond, William L; Thomas, George V; Thompson, Reid F; Wood, Mary A; Koguchi, Yoshinobu; Chen, Yiyi; Latour, Emile; Bergan, Raymond C; Drake, Charles G; Moran, Amy E

NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8(+) T cell responses capable of curing multi-focal cancer.

NKTR-214 免疫疗法与放射疗法协同作用,刺激全身 CD8(+) T 细胞反应,从而治愈多灶性癌症

Walker Joshua M, Rolig Annah S, Charych Deborah H, Hoch Ute, Kasiewicz Melissa J, Rose Daniel C, McNamara Michael J, Hilgart-Martiszus Ian F, Redmond William L